Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

Life sciences leaders are awaiting outcomes of the Section 232 investigation concerning the national security implications of importing pharmaceuticals and related ingredients, which include finished ...

Essential medicines play a vital role in America’s health, and the supply is closely monitored by the FDA and industry groups. These medicines sustain life, provide life support and/or the prevention ...

In many ways, it makes sense for Big Pharma to in-license promising pipeline candidates from smaller companies, effectively using them as an innovation engine and source for pipeline renewal. However, ...

Artificial intelligence is revolutionizing the life sciences industry by driving innovation in various domains, such as drug discovery, clinical trials, and regulatory compliance. While AI offers the ...

The life sciences industry is on the brink of a significant shift. Over the next few years, a historic patent cliff will reshape Big Pharma's landscape, triggering waves of talent movement between ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...